Literature DB >> 2650775

Therapeutic options in chronic myeloid leukaemia.

N C Allan1.   

Abstract

The treatment of CML is unsatisfactory. Only bone marrow transplantation offers the possibility of cure. At present all other therapies are palliative and none has been shown to extend survival consistently. Busulphan and hydroxyurea remain the most widely used drugs for chronic phase. Intensive and non-intensive combination chemotherapy regimens have not produced significant improvement in survival. Interferon therapy is promising in patients who respond but requires further evaluation. Splenectomy does not improve survival but may be useful in selected circumstances. Extramedullary disease carries a poor prognosis and responds best to local treatment. The treatment of blast transformation is very difficult. The lymphoid variety should be recognised as response is better to appropriate treatment. Some Philadelphia (Ph) chromosome negative cases have disease which is probably identical to Ph positive disease and respond well to treatment. The others carry a very bad prognosis and respond poorly to treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2650775     DOI: 10.1016/0268-960x(89)90024-6

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  5 in total

1.  Aerobic or resistance exercise performed the previous day does not attenuate postprandial hyperglycemia-induced endothelial dysfunction in overweight/obese adults.

Authors:  Kevin D Ballard; Craig W Berry; Conlan J Varty; Kristina B Arslain; Kyle L Timmerman
Journal:  Eur J Appl Physiol       Date:  2019-06-11       Impact factor: 3.078

Review 2.  Evolution of therapies for chronic myelogenous leukemia.

Authors:  Fabio P S Santos; Hagop Kantarjian; Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

3.  Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.

Authors:  M Zion; D Ben-Yehuda; A Avraham; O Cohen; M Wetzler; D Melloul; Y Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-25       Impact factor: 11.205

Review 4.  Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.

Authors:  Fabio P S Santos; Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2009-12

5.  Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020).

Authors:  Yue Wang; Liqing Jiang; Baoxuan Li; Yan Zhao
Journal:  Front Oncol       Date:  2022-03-07       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.